2. Search Result
Search Result
Results for "

reactivator

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

4

Peptides

4

Inhibitory Antibodies

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1200
    Pralidoxime chloride

    2-PAM chloride

    		 Cholinesterase (ChE) Neurological Disease
    Pralidoxime chloride is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime chloride reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime chloride is an antidote for organophosphate poisoning .
    Pralidoxime chloride
  • HY-A0280
    Roslin 2 bromide

    Benzylhexamethylenetetramine bromide

    		 MDM-2/p53 FAK Cancer
    Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator with anticancer effects. Roslin 2 bromide binds FAK, disrupts the binding of FAK and p53 .
    Roslin 2 bromide
  • HY-128974
    N-Dodecyl-β-D-maltoside
    3 Publications Verification

    Lauryl Maltoside

    		 Others Others
    N-Dodecyl-β-D-maltoside (Lauryl Maltoside) is a non-ionic detergent. N-Dodecyl-β-D-maltoside has strong adsorption on alumina, titanium dioxide and hematite. N-Dodecyl-β-D-maltoside can promote the reactivation of various proteins. N-Dodecyl-β-D-maltoside can effectively stabilize photoactive reaction center complexes (RCs) and inhibit the degradation of Rhodopseudomonas spheroides R-26 reaction center in solution. N-Dodecyl-β-D-maltoside can be used for purification and stabilization of RNA polymerase and for detection of protein-lipid interactions .
    N-Dodecyl-β-D-maltoside
  • HY-B1738A
    Pralidoxime iodide

    		Cholinesterase (ChE) Neurological Disease
    Pralidoxime iodide is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime iodide reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime iodide is an antidote for organophosphate poisoning .
    Pralidoxime iodide
  • HY-B1738
    Pralidoxime

    		Cholinesterase (ChE) Neurological Disease
    Pralidoxime is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime is an antidote for organophosphate poisoning .
    Pralidoxime
  • HY-12926
    ST7612AA1

    		HIV HDAC DNA/RNA Synthesis Infection
    ST7612AA1 is a histone deacetylase (HDAC) inhibitor that controls chromatin condensation and DNA transcription by removing acetyl groups from histones. ST7612AA1 is also a potent HIV reactivation inducer, and its reactivation activity is exerted without activating or proliferating CD4+T cells, and can be used in the study of HIV reactivation strategies and elimination of viral reservoirs .
    ST7612AA1
  • HY-B1738B
    Pralidoxime methanesulfonate

    		Cholinesterase (ChE) Neurological Disease
    Pralidoxime methanesulfonate is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime methanesulfonate reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime methanesulfonate is an antidote for organophosphate poisoning .
    Pralidoxime methanesulfonate
  • HY-144762
    K027

    		Cholinesterase (ChE) Neurological Disease
    K027 is a potent reactivator of Organophosphates (OP)-inhibited acetylcholinesterase (AChE). K027 can be used for the research of Alzheimer's disease .
    K027
  • HY-B1200R
    Pralidoxime chloride (Standard)

    		Cholinesterase (ChE) Neurological Disease
    Pralidoxime (chloride) (Standard) is the analytical standard of Pralidoxime (chloride). This product is intended for research and analytical applications. Pralidoxime chloride is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime chloride reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime chloride is an antidote for organophosphate poisoning .
    Pralidoxime chloride (Standard)
  • HY-155284
    K1833

    		Cholinesterase (ChE) Neurological Disease
    K1833 is a hrAChE inhibitor/reactivator, with an IC50 of 58 μM. K1833 also shows high inhibition (IC50=0.57μM) and low reactivation for hrBChE .
    K1833
  • HY-156399
    KR-27425

    		Endogenous Metabolite Neurological Disease
    AChE activator 1 (compound 13) is a non-pyridinium oxime reactivator of paraoxon-inhibited acetylcholinesterase(AChE) .
    KR-27425
  • HY-146959
    K203

    		Cholinesterase (ChE) Neurological Disease
    K203 is a potent reactivator of tabun-inhibited AChE. K203 is a crucial antidote used for the organophosphate intoxication .
    K203
  • HY-165600A
    Trimedoxime

    TMB-4

    		 Cholinesterase (ChE) Others
    Trimedoxime (TMB-4) is a potent reactivator of AChE. Trimedoxime shows potency in inducing oxidative stress, with the IC50 of 22 mM .
    Trimedoxime
  • HY-156967
    BAY 1892005

    		MDM-2/p53 Cancer
    BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .
    BAY 1892005
  • HY-160209
    KIO-301

    		Others Cardiovascular Disease
    KIO-301 is a photoswitchable HCN channel blocker, and can be used as the vitreous “light switch” molecule that reactivates retinitis pigmentosa .
    KIO-301
  • HY-19980A
    PRIMA-1
    2 Publications Verification

    NSC-281668

    		 Autophagy MDM-2/p53 Ferroptosis Apoptosis Cancer
    PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    PRIMA-1
  • HY-120122
    PK7088

    		Others Cancer
    PK7088 is a pyrazole and a specific peptide. PK7088 supports the reactivation of mutant p53 by converting it to a form exhibiting wild-type properties. PK7088 exhibit anticancer activity in cancer research .
    PK7088
  • HY-W011108
    Obidoxime dichloride

    		Cholinesterase (ChE) Neurological Disease
    Obidoxime dichloride is a non-full spectrum oxime agent and can be used as an antidote for organophosphate nerve agent poisoning. Obidoxime dichloride reactivates sarin-inhibited acetylcholinesterase (AChE) and reduces acute toxicity of sarin-evaluated .
    Obidoxime dichloride
  • HY-P99572
    Tecaginlimab

    BNT-312; DuoBody-CD40x-4-1BB; GEN1042

    		 TNF Receptor Inflammation/Immunology Cancer
    Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .
    Tecaginlimab
  • HY-141584
    ATSP-7041

    		MDM-2/p53 Cancer
    ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .
    ATSP-7041
  • HY-18634
    NSC319726
    1 Publications Verification

    ZMC1

    		 MDM-2/p53 Cancer
    NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.
    NSC319726
  • HY-123794
    MP07-66

    		Phosphatase Cancer
    MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation .
    MP07-66
  • HY-120012
    Mizacorat
    4 Publications Verification

    AZD9567

    		 Glucocorticoid Receptor Inflammation/Immunology Endocrinology
    Mizacorat (AZD9567; compound 15) is a potent, oral active, non-steroidal and selective glucocorticoid receptor modulator (SGRM), with an IC50 of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of joint inflammation .
    Mizacorat
  • HY-103397
    Nanaomycin A
    2 Publications Verification

    		 DNA Methyltransferase Parasite Infection Cancer
    Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells . Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM .
    Nanaomycin A
  • HY-13642
    RG108
    5+ Cited Publications

    N-Phthalyl-L-tryptophan

    		 DNA Methyltransferase Cancer
    RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences .
    RG108
  • HY-P10652
    hsBCL9CT-24

    		Wnt β-catenin Cancer
    hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
    hsBCL9CT-24
  • HY-149886
    HIF-2α-IN-9

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC50=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .
    HIF-2α-IN-9
  • HY-P3139
    TPP-1

    		PD-1/PD-L1 Cancer
    TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .
    TPP-1
  • HY-122753
    SLMP53-1

    		MDM-2/p53 Cancer
    SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .
    SLMP53-1
  • HY-119490
    UMB-136

    		Epigenetic Reader Domain HIV Infection
    UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb .
    UMB-136
  • HY-100468
    REV7/REV3L-IN-1

    		Others Cancer
    REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC50 of 78 μM, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter and reporter regions .
    REV7/REV3L-IN-1
  • HY-130514
    SMAPP1

    		HIV CDK Infection
    SMAPP1 is an activator of protein phosphatase-1 (PP1). SMAPP1 increases phosphorylation of CDK9’s Ser90 and Thr186 residues, but not Ser175. SMAPP1 induces HIV-1 replication, upregulates HIV-1 transcription that led to the reactivation of latent HIV-1 provirus .
    SMAPP1
  • HY-P3139A
    TPP-1 TFA

    		PD-1/PD-L1 Cancer
    TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .
    TPP-1 TFA
  • HY-161138
    WK369

    		BCL6 Apoptosis Cancer
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
    WK369
  • HY-A0084
    Procainamide hydrochloride
    4 Publications Verification

    Procaine amide hydrochloride; SP 100 hydrochloride

    		 DNA Methyltransferase Potassium Channel Cancer
    Procainamide hydrochloride (Procaine amide hydrochloride) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide hydrochloride induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide hydrochloride relaxes airway smooth muscle by activating potassium channels. Procainamide hydrochloride can be used in cancer and arrhythmia research .
    Procainamide hydrochloride
  • HY-A0084A
    Procainamide
    4 Publications Verification

    Procaine amide; SP 100

    		 DNA Methyltransferase Potassium Channel Cardiovascular Disease Cancer
    Procainamide (Procaine amide) is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1), which reactivates the expression of tumor suppressor factors by demethylating tumor suppressor genes. Procainamide induces vacuolization in various cell types and reduces cell proliferation and migration. Procainamide relaxes airway smooth muscle by activating potassium channels. Procainamide can be used in cancer and arrhythmia research .
    Procainamide
  • HY-143653
    BCL6-IN-6

    		BCL6 Cancer
    BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .
    BCL6-IN-6
  • HY-161344
    Z36-MP5

    		Others Cancer
    Z36-MP5 is an Mi-2β-targeted inhibitor, with IC50 of 0.082 μM. Z36-MP5 can reduce Mi-2β ATPase activity and reactivates ISG transcription. Z36-MP5 can stimulate T-cell-mediated cytotoxicity .
    Z36-MP5
  • HY-149577
    EBV lytic cycle inducer-1

    		EBV Cancer
    Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers .
    EBV lytic cycle inducer-1
  • HY-N0401A
    (Z)-Ligustilide
    3 Publications Verification

    		 Bacterial Estrogen Receptor/ERR FATP Infection Metabolic Disease
    (Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
    (Z)-Ligustilide
  • HY-P99623
    Flotetuzumab

    MGD006; S80880

    		 CD3 Cancer
    Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
    Flotetuzumab
  • HY-13207
    ONX-0914
    Maximum Cited Publications
    15 Publications Verification

    PR-957

    		 Proteasome Bacterial HIV Infection Inflammation/Immunology
    ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
    ONX-0914
  • HY-153202
    SLMP53-2

    		MDM-2/p53 Apoptosis Cancer
    SLMP53-2 is a mutant p53 reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .
    SLMP53-2
  • HY-13207A
    ONX-0914 TFA
    Maximum Cited Publications
    15 Publications Verification

    PR-957 TFA

    		 Proteasome Bacterial HIV Infection Inflammation/Immunology
    ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
    ONX-0914 TFA
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-148833
    MDM2-p53-IN-16

    		MDM-2/p53 Cancer
    MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
    MDM2-p53-IN-16
  • HY-149132
    Dendrogenin A

    DDA

    		 LXR Cancer
    Dendrogenin A (DDA) is a ligand for liver X receptor (LXR), that induces the expression of sodium/iodine symporter, and increases iodine uptake. Dendrogenin A induces cell differentiation of MCF-7, and reactivates the function of lactating cells. Dendrogenin A induces the expressions of the TSH receptor, thyroid peroxidase, and thyroglobulin, and affects thyroid hormone generation. Dendrogenin A exhibits cytotoxicity in cancer cell B-CPAP and 8505c with IC50 of 4.1 and 6.2 µM. Dendrogenin A arrests the cell cycle at G0/G1 phase .
    Dendrogenin A
  • HY-109139
    Taminadenant
    1 Publications Verification

    NIR178; PBF509

    		 Adenosine Receptor Neurological Disease Cancer
    Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
    Taminadenant
  • HY-15815
    Bromosporine
    3 Publications Verification

    		 Epigenetic Reader Domain Apoptosis CDK HIV Cancer
    Bromosporine is a potent BET inhibitor with an IC50 value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .
    Bromosporine
  • HY-19896
    COTI-2
    2 Publications Verification

    		 MDM-2/p53 Apoptosis Cancer
    COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
    COTI-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: